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Abstract 30 
 31 
Multidrug-resistant tuberculosis (MDR-TB) in low-incidence countries in Europe is more prevalent 32 
among migrants than the native population. The impact of the recent increase in migration to EU 33 
and EEA countries with a low incidence of TB (fewer than 20 cases per 100,000 [1]) on MDR-TB 34 
epidemiology is unclear. This narrative review synthesises evidence on MDR-TB and migration 35 
identified through an expert panel and database search. A significant proportion of MDR-TB cases in 36 
migrants result from reactivation of latent infection. Refugees and asylum seekers may have a 37 
heightened risk of MDR-TB infection and worse outcomes. Although concerns have been raised 38 
around ‘health tourists’ migrating for MDR-TB treatment, numbers are probably small and data are 39 
lacking. Migrants experience significant barriers to testing and treatment for MDR-TB, exacerbated 40 
by increasingly restrictive health systems. Screening for latent MDR-TB is highly problematic since 41 
current tests cannot distinguish drug-resistant latent infection, and evidence-based guidance for 42 
treatment of latent infection in contacts of MDR patients lacking. While there is evidence that 43 
transmission of TB from migrants to the general population is low – it predominantly occurs within 44 
migrant communities – there is a human rights obligation to improve the diagnosis, treatment, and 45 
prevention of MDR-TB in migrants. Further research is needed into MDR-TB and migration, the 46 
impact of screening on detection or prevention, and the potential consequences of failing to treat 47 
and prevent MDR-TB among migrants in Europe. An evidence-base is urgently needed to inform 48 
guidelines for effective approaches for MDR-TB management in migrant populations in Europe.    49 
Key words 50 
Tuberculosis; drug resistance; migration; Europe; screening; health service delivery; latent 51 
tuberculosis; MDR-TB  52 
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Introduction 53 
 54 
Multidrug-resistant tuberculosis (MDR-TB) is an urgent public health priority in Europe, with 55 
significant health and cost implications associated with the expensive and prolonged treatment 56 
often required [2]. Migration to and within Europe has increased dramatically in recent years [3, 4], 57 
and in many EU and EEA countries with a low incidence of TB (e.g. fewer than 20 cases per 100,000 58 
[1]), rates of MDR-TB have been shown to be higher among migrants (‘foreign-born’) than the 59 
general population [5-7]. There is evidence both for MDR-TB being imported to Europe by migrants 60 
[8] and for MDR-TB being acquired or transmitted within Europe [9, 10]. Although surveillance data 61 
demonstrate that rates of drug resistance in most Western European countries remain low (<3% in 62 
new cases) [11], this may increase with migration from high MDR-TB burden countries, particularly 63 
those in Eastern Europe with the highest risk of MDR-TB among TB cases [12].   64 
 65 
The diverse migrant population in Europe, including forced migrants (asylum seekers and refugees), 66 
undocumented migrants residing in Europe without legal status, or those migrating for family, work, 67 
or study, is estimated to include over 30 million individuals born outside the European Union (EU), 68 
and more than 17 million migrants from other EU Member States [13]. In 2015 alone, more than 1 69 
million migrants entered Europe during the migrant crisis [14]. A cohesive evidence-base on the 70 
impact of migration on MDR-TB in Europe is essential to guide policy and practice around the 71 
identification and treatment of MDR-TB.  72 
 73 
This narrative review examines the relationship between MDR-TB and migration in low- incidence 74 
EU countries.  We consider the implications of MDR-TB for individual migrants and their 75 
communities, and for public health policy and practice.   76 
 77 
Methods 78 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4 
In this paper, we systematically identified evidence on MDR-TB and migration through a database 79 
search including Embase, Medline, Global Health, and Google Scholar, as well as an expert panel 80 
which contributed to the identification of relevant research, integrating diverse views to reduce 81 
bias. 82 
 83 
Epidemiology of migration and MDR-TB 84 
 85 
MDR-TB is widespread globally, with an estimated 480 000 cases in 2014 [15] and significant 86 
disparities between countries and regions. In Russia, Bangladesh, and China, the proportion of 87 
previously treated TB cases that are multidrug-resistant is 49%, 29%, and 26% respectively [15]. In 88 
Eastern Europe, the proportion of previously treated TB cases that are multidrug-resistant is 69.0% 89 
in Belarus, 62.0% in Moldova and Estonia, 56.0% in Ukraine, 49.0% in Lithuania, 30% in Latvia, and 90 
23.0% in Bulgaria [16, 17]. Many of these countries also have high rates of MDR-TB in new cases, for 91 
example Belarus (34%), Moldova (24%), Ukraine (22%), and Estonia (19%) [15]. The high rates of 92 
MDR-TB in these countries are in part due to disparities in the availability of high-quality treatment 93 
[17].  94 
 95 
Low incidence TB countries in Europe are receiving increasing numbers of migrants from high-96 
incidence countries, who are over-represented among MDR-TB cases. Across EU and EEA Member 97 
States, reported surveillance data suggest 73.4% of MDR-TB cases are in migrants (born outside of 98 
the reporting country) [18], among whom, 51.7% of MDR-TB cases occur in migrants originating 99 
from the EU [19].  In Germany, migrants comprise 94.0% of MDR-TB cases, though only 58.7% of TB 100 
cases.  Similarly, in the UK migrants comprise 90.4% of MDR-TB cases, but only 69.1% of TB cases, 101 
and in France migrants account for 89.2% of MDR-TB infections, though only 55.6% of TB cases 102 
(Table 1) . 103 
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 104 
The proportion of the population in a selection of European countries that is foreign born, as well as 105 
the proportion of notified cases of TB and MDR-TB that occur in migrants, is shown in Figure 1.  This 106 
figure illustrates that in much of North and Western Europe, migrants are over-represented among 107 
cases of TB, and particularly MDR-TB, given their distribution in the general population. The figure 108 
also points to disparities between Western and Eastern Europe, with migrants comprising a low 109 
proportion of TB and MDR-TB cases in Lithuania and Romania, which can be attributed both to the 110 
low rates of migration and high incidence of TB (and particularly MDR-TB).  Other research and 111 
surveillance data also highlight disparities in rates of TB and MDR-TB within Europe [20].     112 
 113 
A significant proportion of cases of MDR-TB in migrants in low-incidence countries are likely to result 114 
from reactivation of latent infection acquired prior to migration [21]. Reactivation of latent TB most 115 
often occurs in the first 2-5 years following migration [22], which may be partly attributed to poor 116 
living conditions and barriers to accessing health services [6, 23]. his increased risk may persist in 117 
migrants in comparison to the general population [24]. 118 
 119 
There is some evidence that a significant proportion of TB cases (new infection or reinfection) 120 
among migrants result from re-exposure during return visits to their home countries, often to visit 121 
friends or relatives [25], yet data on MDR-TB infection acquired by this route are lacking. It is 122 
important to note that migrant communities often cluster together in host countries, and disease is 123 
therefore more likely to spread within their own communities, rather than to the surrounding host 124 
population [26, 27]. 125 
 126 
Migrants at high risk of MDR-TB  127 
 128 
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Migrants fleeing conflict or other violence (e.g. the current influx of asylum seekers entering Europe 129 
from the Middle East and Africa), may be at increased risk of TB and MDR-TB [24] due to the collapse 130 
of health service infrastructure in the context of conflict. The breakdown of health systems has been 131 
shown to contribute to an increase in TB incidence, may also be a risk factor for the development of 132 
MDR-TB [28, 29].  Some migrant groups including refugees, refused asylum seekers, victims of 133 
trafficking, and undocumented migrants may be at particularly high risk of MDR-TB due to exposure 134 
to destitution, poor social conditions (e.g. overcrowding, poor living conditions, incarceration or 135 
detention, and homelessness), exposure to other migrants from high-incidence countries during 136 
their migration trajectory, or co-infection (e.g. with HIV). These migrant groups may also be excluded 137 
from health services or be fearful of accessing services due to their legal status, preventing them 138 
from accessing free screening, diagnosis, or treatment [30]. However, empirical evidence on the risk 139 
of MDR-TB in these groups, or their general health needs, are insufficient. 140 
 141 
There is also a relatively small group –  in the context of the current mass movement of populations 142 
– of “health tourists” who migrate or travel with the specific aim of seeking treatment for MDR-TB 143 
[31]. These individuals may have previously received treatment, but failed multiple courses of 144 
therapy in their home countries, and migrate to access better treatment options [8]. Within this 145 
group, there is a small proportion of relatively affluent patients able to pay themselves for 146 
treatment. Recently concerns have been raised around the implications of health tourism for 147 
European health services and the wider public health [32, 33]. Disparities in rates of TB and MDR-TB 148 
between low-incidence countries in Europe and high-incidence countries globally, and inequalities in 149 
the distribution of resources (including in the availability and affordability of treatment) may be 150 
drivers of this, and have been particularly highlighted between Western and Eastern Europe [17]. 151 
Overall, however, data on patterns of health tourism are lacking.  152 
 153 
Diagnosis of MDR-TB and screening strategies  154 
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 155 
There are significant challenges to drug susceptibility testing (DST) to diagnose MDR-TB and the 156 
accurate collection of surveillance data on MDR-TB globally. Despite the rollout of rapid molecular 157 
diagnostics including Xpert MTB/RIF and line probe assays [34, 35], diagnostic delays are common 158 
and only 123,000 cases with MDR-TB were notified globally in 2014 [36].  In many high-incidence 159 
countries, access is limited to culture-based phenotypic drug sensitivity testing (DST) for first-line 160 
and second-line drugs (which takes weeks), although the second line Hain line probe assay was 161 
recently recommended by WHO as the initial test for detection of resistance to fluoroquinolones and 162 
second-line injectable drugs [37]. Migrants from high-incidence countries may therefore have a high 163 
risk of previously undiagnosed or incorrectly diagnosed drug resistance.  164 
 165 
Most low-incidence countries have policies to systematically screen migrants from TB-endemic 166 
countries for active TB [38], with a limited number of countries in Europe also implementing latent 167 
TB (LTBI) screening [39].  There is conflicting evidence on the most effective and cost-effective 168 
strategy for migrant TB screening, and there is significant variation in national approaches to 169 
screening [38-41], which can be explained by the weak evidence-base on the effectiveness of 170 
migrant TB screening as well as heterogeneous political environments [26].  Furthermore, though 171 
screening may be implemented, there is a lack of systematic follow-up procedures for migrants 172 
across Europe [39], which are necessary for adequate care and efforts to eliminate TB. 173 
 174 
Yield of screening for active TB often corresponds to the epidemiology in the country of origin. 175 
However, large variations may occur due to differences in the profile of sub-populations of migrants, 176 
as well as varying risk of TB transmission and progression during the migration process [40, 42]. This 177 
is likely to be true also for the proportion of patients with MDR-TB.  However, very little data have 178 
been reported specifically on yield of MDR-TB. Of 15 screening studies included in a recent 179 
systematic review on pre-entry screening programmes for TB in migrants to low-incidence countries, 180 
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only three reported data on the number of cases of MDR-TB identified within culture-confirmed 181 
cases of active TB [42]. Due to the lack of screening outcome data from surveillance systems [40, 42], 182 
as well as very limited specific research on MDR-TB in the context of migrant screening, the potential 183 
impact on early detection and interruption of MDR-TB transmission remains largely unknown. 184 
However, transmission of TB from migrants to the general population typically is low in host 185 
countries with good health-care access for migrants [26, 43-46]. 186 
 187 
Screening for latent MDR-TB is highly problematic since current tests (tuberculin skin test and 188 
interferon-gamma release assays) cannot distinguish between drug-susceptible and drug-resistant 189 
TB, and cannot predict risk of reactivation. Moreover, the best chemoprophylaxis for individuals with 190 
suspected latent MDR-TB has not yet been established. There is extremely limited data on the 191 
effectiveness of chemoprophylaxis for suspected MDR-TB [47, 48].  Furthermore, WHO did not 192 
recommend systematic prophylaxis with second-line TB drugs in contacts of patients with MDR-TB in 193 
its recent guidelines [49]. Clinical trials are needed to inform any future recommendations.   194 
 195 
Treatment outcomes in migrants 196 
 197 
Globally, only 50% of MDR-TB patients successfully complete treatment, with 24% lost to follow up 198 
or without outcome information [15]. For extensively drug-resistant TB (XDR-TB), only 26% of 199 
patients successfully complete treatment, with 25% lost to follow-up or without outcome 200 
information [15]. This gap is greater in countries with a higher prevalence of drug-resistance [15], 201 
and is relevant to low-incidence countries in the context of migration.   202 
 203 
Some data suggest that migrants treated in low-incidence European countries are less likely to have 204 
successful treatment outcomes for MDR-TB than host populations.  In a cohort study on treatment 205 
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outcomes for MDR-TB patients in the UK, 72.3% of migrants had a successful treatment outcome, 206 
compared with 90% of UK born (OR 0.29 [0.08-1.01]; p=0.026)[50]. This may be attributed to formal 207 
and informal barriers to testing and treatment – including fears relating to legal status or 208 
government, language and health literacy, lack of entitlement to services, and inability to pay – 209 
resulting in delays in presentation and poor treatment outcomes.  Such barriers are likely to be 210 
exacerbated by increasingly restrictive health systems across Europe [3]. The intensive, complex, and 211 
lengthy treatment, and high pill burden, as well as contextual factors like alcohol or drug use, 212 
homelessness, and social stigma may further impact on treatment uptake and adherence for TB and 213 
MDR-TB. These factors undoubtedly contribute to the acquisition of drug resistance [6, 23, 24, 40, 214 
51]. 215 
 216 
However, the migration status of patients is often not recorded, and research findings are 217 
inconsistent [52].  The limited data on treatment outcomes for MDR-TB in migrants in low-incidence 218 
countries in Europe point to the need for further research in these communities, as well as the need 219 
for strategies to improve the identification and treatment of MDR-TB in these hard-to-reach groups. 220 
This is particularly pertinent in light of the shorter MDR-TB regimen now recommended by WHO 221 
[53], which may help to improve treatment completion and cure, although further trial data are 222 
awaited. 223 
 224 
Resource implications of treating and preventing MDR-TB in migrants 225 
 226 
Less than 25% of MDR-TB patients globally have been started on treatment, yet it is unclear how 227 
many of these patients are migrants residing in low-incidence countries in Europe [54]. A recent 228 
systematic review reported that the costs of treating MDR-TB (from the provider perspective) were 229 
between US $1218 - $83,365 (in low- to high-income countries) in comparison to US $258 - $14,659 230 
for drug-sensitive TB [55]. The highest proportion of costs incurred is due to hospitalisation (which is 231 
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often extensive in some high MDR-TB burden settings such as Russia), followed by drugs and clinic 232 
visits.  233 
Given the potential costs for host country health systems associated with the identification and 234 
treatment of TB among migrants, there may be advantages in supporting MDR-TB control efforts in 235 
countries with high MDR-TB incidence.  A decision analysis suggested that it may be cost saving for 236 
low-incidence countries to support improved TB care and prevention in high-incidence source 237 
countries for migrants [56].  Such strategies may be particularly effective for MDR-TB, given the 238 
increased costs associated with MDR-TB treatment, and should be further investigated. 239 
  240 
A cost-effectiveness analysis has shown that outpatient-based models could lower costs per 241 
disability adjusted life year (DALY) by as much as 54% compared with inpatient-based models [57]. 242 
However, in low-incidence countries there may be an emphasis on the hospitalisation of MDR-TB 243 
cases, and isolation within the hospital context to prevent spread of disease, leading to increased 244 
costs. Migrants are particularly vulnerable to the social and economic consequences of TB and MDR-245 
TB and costs associated with treatment, and thus specific social and financial support may be 246 
needed to facilitate screening and treatment in these communities [58].  Technology based 247 
interventions including video observed therapy (VOT), mobile phone communication, or social media 248 
based health literacy may be help overcome  barriers to screening and treatment adherence in 249 
migrants [59]. The effectiveness of existing protocol (e.g. risk assessments for low treatment 250 
adherence carried out by TB services, and how this informs decisions about treatment options) 251 
should also be assessed. 252 
 253 
Further research into effective and cost-effective strategies to increase the detection and treatment 254 
of MDR-TB in hard-to-reach migrant populations in low-incidence countries is needed to provide 255 
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more insight into the trade-offs between intensified screening, investment in accessible and 256 
effective clinical care, and social support for at risk migrant groups to facilitate engagement with 257 
services.  Whilst these strategies may be costly, it is essential to prioritise the availability and 258 
accessibility of care.  Screening cannot be meaningful without linkage to high-quality care, which 259 
ultimately is necessary to reduce migrant mortality and morbidity, as well as transmission to the 260 
wider population. 261 
 262 
Conclusions and action points 263 
 264 
MDR-TB is more prevalent in migrant populations in low-incidence countries in Europe than host 265 
populations. At a time when large numbers of migrants from high-incidence countries are migrating 266 
to Europe, there is insufficient data on the prevalence of MDR-TB among migrants, or the impact on 267 
incidence in receiving countries. MDR-TB may be acquired before, as well as during or following 268 
migration, due to barriers to accessing services, low treatment adherence, or increased risk of 269 
infection due to social conditions in transit or in host countries. While transmission predominantly 270 
occurs between migrants, there is a risk of transmission for both migrants and the native population. 271 
Key findings and points of action are summarised in Table 2.  272 
There is a clear imperative to optimise the quality of diagnosis, treatment, and prevention of MDR-273 
TB in migrants. Barriers to care include restrictions on access to health care for migrants as well as 274 
informal barriers to service uptake. In some instances, disparities in the availability of services (e.g. 275 
between Eastern and Western European countries) may lead to health tourism. Compounding these 276 
challenges is the lack of a diagnostic test to detect latent MDR-TB and to predict the risk of disease 277 
re-activation, and high-quality evidence for an effective prophylactic drug regimen. 278 
 279 
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Key research gaps include a lack of data on effective screening strategies for MDR-TB or how routine 280 
practice should be adapted across diverse health systems in Europe to improve treatment outcomes 281 
in migrants at risk of low adherence to TB treatment or with MDR-TB. There are also insufficient data 282 
on specific risk factors for MDR-TB, patterns of acquisition and transmission, and treatment 283 
outcomes in migrants in low-incidence countries in Europe. The limited evidence-base means that 284 
there are currently shortfalls in the delivery of effective and cost-effective screening and treatment 285 
strategies in migrants. Improved routine public health surveillance, as well as further research, is 286 
undoubtedly needed to better understand the relationship between MDR-TB and migration, the 287 
impact screening may have on early detection or prevention, and to quantify the consequences 288 
associated with a failure treat and prevent MDR-TB among migrants in Europe.  289 
Improving the detection and treatment of infectious diseases in migrants is essential in order to 290 
improve the health status of migrants, and host countries must acknowledge their obligation to 291 
migrants’ human right to health. Specifically, there should be an emphasis on targeting migrants 292 
from high TB incidence countries to improve the detection of MDR-TB (e.g. routinely testing all 293 
migrants with TB for drug resistance), and facilitating access to treatment (e.g. free MDR-TB 294 
diagnosis and treatment in any EU country, and culturally competent care [60]). The development of 295 
coherent guidelines is also a crucial next step to ensure the roll out of effective and cost-effective 296 
approaches to the management and prevention of MDR-TB in migrant populations in low-incidence 297 
countries in Europe.  298 
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Figure legend: 453 
Figure 1 MDR-TB and migration in Europe* 454 
The boxes in this figure illustrate the proportion of TB cases and MDR-TB cases that occur in 455 
migrants (blue stacks) in each country. Columns in the boxes represent the percentage of foreign 456 
born overall, among the total tuberculosis (TB) and multi-drug resistant TB (MDR-TB) cases reported 457 
in that country. On the map, the different shadings of the countries represent the proportions of 458 
foreign-born individuals living in that country that are comprised by migrants.   459 
*Data [12, 15-21, 23, 24, 61] 460 
 461 
 462 
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Table 1 TB and MDR-TB in migrants in Europe 
Country Year of 
report 
Total number 
of TB cases [n] 
Total number of 
migrants with TB 
[n (%)] 
Total 
number of 
MDR-TB 
cases [n] 
Total number 
of migrants 
with MDR-TB [n 
(%)] 
Austria 2014 582 374 (64.3%) 20 20 (100.0%) 
Denmark 2010 359 216 (60.2%) 2 1 (50.0%) 
France 2014 4845 2692 (55.6%) 111 99 (89.2%) 
Germany 2014 4488 2635 (58.7%) 89 79 (94.0%) 
Italy 2010 3249 1809 (5.6%) 87 76 (87.4%) 
Lithuania 2010 1938 47 (2.4%) 506 11 (2.2%) 
The 
Netherlands 
2014 823 602 (73.1%) 6 6 (100.0%) 
Norway 2014 325 302 (92.9%) 10 10 (100.0%) 
Portugal 2014 2264 360 (15.9%) 23 5 (21.7%) 
Romania 2010 21078 38 (0.2%) 502 0 (0.0%) 
Spain 2014 5018 1446 (28.8%) 35 19 (54.3%) 
United 
Kingdom 
2014 7077 4890 (69.1%) 52 47 (90.4%) 
Data: [26, 32, 40, 41, 61-67] 
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Table 1 Key findings and points of action 
Key Findings Points of action 
Problem 
• MDR-TB widespread globally: 480,000 
cases of MDR-TB or XDR-TB in 2014  
• Migration from high MDR-TB burden 
countries may contribute to increase in 
MDR-TB case notification rates in low-
incidence countries 
• Risk of MDR-TB higher among migrants 
in low-incidence countries in Europe 
than general population 
• No screening test for latent MDR-TB 
• MDR-TB infection may be acquired 
through return travel to country of 
origin visiting friends and family 
• New infection or re-infection of MDR-
TB due to poor social conditions and 
barriers to health care on arrival  
• Barriers to health services prevent the 
effective detection and treatment of 
MDR-TB in migrants, both in country of 
origin and in the host country 
Access to services 
• Facilitate access to diagnosis and 
effective follow-up and treatment for 
migrants 
• Policies restricting free access to 
statutory health services in European 
host countries need addressing: they 
present barriers to diagnosis and 
treatment, which may increase risk of 
transmission and acquisition of MDR-TB 
• Develop social and financial support 
mechanisms for migrant patients 
Screening and treatment guidelines 
• Significant variations in screening 
strategies for migrants in Europe due to 
weak evidence base and 
heterogeneous political environments 
• Need for consistency in policy and 
practice across Europe, as well as 
development of evidence based 
guidelines for the prevention and 
treatment of MDR-TB in migrants 
Research 
• Need for further research on MDR-TB in 
migrants to provide robust evidence 
base for policy and practice 
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